CASC3 and Miyoshi myopathy: Interestingly, by analyzing three additional cohorts of BTZ-treated MM patients, we found that increased activity of SC2 marker genes was associated with worse patient overall survival (Fig. 4k) and disease-free survival (Fig. 4l), and relapsed patients exhibited higher SC2 marker genes activity than non-relapsed group (Supplementary Fig. 22e).